Incyte (INCY) Other Non-Current Liabilities (2013 - 2026)
Incyte's (INCY) quarterly Other Non-Current Liabilities came in at $124.5 million in Q2 2026, down 30.79% YoY from $179.9 million in Q2 2025, and down 1.64% on a QoQ basis from $126.6 million in Q1 2026.
Analysis
Incyte (INCY) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends
Incyte (INCY) has 14 years of Other Non-Current Liabilities data on file, last reported at $124.5 million in Q2 2026.
- Quarterly Other Non-Current Liabilities fell 30.79% year-over-year to $124.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $124.5 million (down 30.79% YoY) and the FY2025 annual result came in at $165.3 million, down 1.36% from the prior year.
- Other Non-Current Liabilities retreated to $124.5 million in Q2 2026, from $126.6 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $204.1 million in Q1 2022 to a low of $124.5 million in Q2 2026.
- A 5-year average of $170.2 million and a median of $171.5 million in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2025 — Other Non-Current Liabilities climbed 14.71% — and 2026, when it slumped 30.79%.
- Tracing INCY's Other Non-Current Liabilities over 5 years: stood at $184.5 million in 2022, then slipped by 5.9% to $173.6 million in 2023, then decreased by 3.48% to $167.5 million in 2024, then declined by 1.36% to $165.3 million in 2025, then declined by 24.66% to $124.5 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $124.5 million (Q2 2026), $126.6 million (Q1 2026), and $165.3 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 124.52 Mn |
| Mar 31, 2026 | 126.59 Mn |
| Dec 31, 2025 | 165.27 Mn |
| Sep 30, 2025 | 171.18 Mn |
| Jun 30, 2025 | 179.91 Mn |
| Mar 31, 2025 | 175.59 Mn |
| Dec 31, 2024 | 167.54 Mn |
| Sep 30, 2024 | 166.67 Mn |
| Jun 30, 2024 | 156.85 Mn |
| Mar 31, 2024 | 164.84 Mn |
| Dec 31, 2023 | 173.58 Mn |
| Sep 30, 2023 | 170.19 Mn |
| Jun 30, 2023 | 179.49 Mn |
| Mar 31, 2023 | 180.83 Mn |
| Dec 31, 2022 | 184.46 Mn |
| Sep 30, 2022 | 171.81 Mn |
| Jun 30, 2022 | 200.09 Mn |
| Mar 31, 2022 | 204.13 Mn |
| Dec 31, 2021 | 206.99 Mn |
| Sep 30, 2021 | 213.78 Mn |